8-K: Picard Medical Launches MedTech Podcast Series

Picard Medical, parent company of SynCardia Systems, announced the launch of the 'Cruxx to MedTech Podcast' series, exploring its SynCardia Total Artificial Heart and the next-generation Emperor device.

Summary

• Picard Medical, Inc. (PMI) launched the 'Cruxx to MedTech Podcast' series on January 13, 2026.
• The podcast explores the SynCardia Total Artificial Heart (STAH) and the next-generation, fully implantable Emperor device.
• The series features patient survival stories highlighting the real-world impact of STAH on end-stage heart failure patients.
• Management discusses the STAH platform, its differentiation from other approaches, and the long-term vision to provide a true alternative to heart transplantation.
• The company sees a significant commercial opportunity driven by the global shortage of donor hearts.
• The podcast will be available on major platforms including Apple Podcasts, Spotify, and Google Podcasts, and Cruxx's website.

Sentiment

Score: 7

Explanation: The announcement is promotional, highlighting the company's technology, patient impact, and future vision. It aims to generate positive awareness and reinforce market position, indicating a generally positive sentiment without disclosing new financial performance data.

Positives

• Launch of a new podcast series to increase awareness and educate about SynCardia's technology.
• Highlighting patient survival stories demonstrates the real-world impact and efficacy of the SynCardia Total Artificial Heart (STAH).
• Management emphasizes the clear differentiation of STAH compared to other approaches.
• The company has a long-term vision to create a true alternative to heart transplantation.
• Identified a significant commercial opportunity due to the global shortage of donor hearts.
• SynCardia Total Artificial Heart is the world's first FDA and Health Canada approved artificial heart and the only commercially available one in the US and Canada.
• Over 2,100 STAH implants have been performed at hospitals across 27 countries, making it the most widely used and studied artificial heart globally.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ.
• Numerous conditions, many beyond the company's control, could impact results, as detailed in the Risk Factors section of the Registration Statement and related prospectus filed with the SEC.

Future Outlook

The company's long-term vision is to create a true alternative to heart transplantation, addressing the significant commercial opportunity presented by the global shortage of donor hearts. The next-generation, fully implantable Emperor device is part of this future strategy.

Management Comments

• Outlines the Company's STAH platform and its next generation fully implantable Emperor system.
• Highlights the clear differentiation of STAH compared to other approaches.
• The Company's long-term vision to create a true alternative to heart transplantation.
• The significant commercial opportunity driven by the global shortage of donor hearts.

Industry Context

The launch of the 'Cruxx to MedTech Podcast' positions Picard Medical and SynCardia within the broader medical technology landscape, specifically addressing the critical area of end-stage heart failure. By highlighting patient stories and management's vision, the company aims to reinforce its leadership in artificial heart technology, a niche but vital segment of the cardiovascular device market. The focus on the global donor heart shortage underscores the ongoing need for innovative mechanical circulatory support solutions.

Comparison to Industry Standards

• SynCardia Total Artificial Heart (STAH) is highlighted for its "clear differentiation compared to other approaches," though specific competing devices or companies are not named in the filing.
• STAH is noted as the "world's first total artificial heart approved by both the U.S. FDA and Health Canada," setting a benchmark for regulatory achievement in the field.
• It remains the "only commercially available artificial heart in the United States and Canada," indicating a unique market position.
• With "more than 2,100 implants performed at hospitals across 27 countries," STAH is presented as the "most widely used and extensively studied artificial heart in the world," suggesting a leading position in terms of clinical experience and adoption.

Stakeholder Impact

• Patients: The podcast highlights patient survival stories, potentially offering hope and information to those with end-stage heart failure.
• Shareholders/Investors: The announcement aims to raise awareness of the company's technology, market position, and future potential, potentially influencing investor perception.
• Medical Community: The podcast provides a platform for discussing advanced medical technology like STAH and the Emperor device, potentially informing healthcare professionals.
• Employees: Reinforces the company's mission and achievements, potentially boosting morale.

Next Steps

• The Cruxx to MedTech Podcast will be available for download and streaming on all major platforms, including Apple Podcasts, Spotify, and Google Podcasts.
• The podcast will also be available directly on Cruxx's website.

Key Dates

Keywords

Picard Medical, SynCardia, Total Artificial Heart, Emperor device, MedTech, Heart Failure, Artificial Heart, Medical Devices, Cardiovascular, FDA Approved, Health Canada Approved, Podcast